A securities class action has been filed in the USDC – DE. against Apellis Pharmaceuticals, Inc. (APLS) (“Apellis” or the “Company”) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Apellis securities between January 28, 2021 through July 28, 2023, both dates inclusive (the “Class Period”).

Apellis is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that:

• • the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections;

  • as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and

  • therefore, Defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis, thereby causing investors to suffer damages.

If you purchased Apellis securities during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.